



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/70</b>	<b>A2</b>	(11) International Publication Number: <b>WO 98/00118</b> (43) International Publication Date: 8 January 1998 (08.01.98)
<p>(21) International Application Number: PCT/US97/12545</p> <p>(22) International Filing Date: 3 July 1997 (03.07.97)</p> <p>(30) Priority Data: 60/012,124 3 July 1996 (03.07.96) US</p> <p>(71) Applicant: ALZA CORPORATION [US/US]; 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).</p> <p>(72) Inventors: ENSCORE, David, J.; 2 Red Oak Drive, Sudbury, MA 01776 (US). CAMPBELL, Patricia, S.; 1410 Middlefield Road, Los Altos, CA 94301 (US). NEDBERGE, Diane, E.; 473 Arboleda Drive, Los Altos, CA 94024-4111 (US). FRAME, Richard, D.; 5043 Cape May Avenue, San Diego, CA 92017 (US).</p> <p>(74) Agents: RAFA, Michael, J. et al.; Alza Corporation, 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).</p>	<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: DRUG DELIVERY DEVICES AND PROCESS OF MANUFACTURE</p> <p>(57) Abstract</p> <p>An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.</p> <div data-bbox="755 1134 1485 1417"> </div>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1                                   **DRUG DELIVERY DEVICES**  
2                                   **AND PROCESS OF MANUFACTURE**

3  
4                                   **FIELD OF INVENTION**

5  
6                   This invention relates to an improved process for the manufacture of  
7 drug delivery devices and to drug delivery devices produced thereby. The  
8 improvement comprises a heat equilibration process which controls the  
9 migration of a drug from the drug reservoir through the adjoining layers of  
10 the device. Preferably, this process enables improved control over the  
11 concentration of the drug in the body contacting layer, such as the contact  
12 adhesive layer of a transdermal device, resulting in greater control of the  
13 initial loading dose of drug delivered by such devices. The process has  
14 particular application in the manufacture of transdermal drug delivery devices  
15 comprising a drug reservoir containing a drug at or above saturation.

16  
17                                   **BACKGROUND OF THE INVENTION**

18  
19                   Transdermal delivery devices for the delivery of a wide variety of  
20 drugs have been known for some time. Typical devices range from simple  
21 monolithic devices such as disclosed in US Patent No. 4,758,434, to devices  
22 including in-line adhesives and release rate controlling membranes as  
23 disclosed in 3,598,122, 3,598,123, 3,742,951, 4,031,894, 4,060,084,  
24 4,144,317, 4,201,211, and 4,379,454. Such rate-controlled devices generally  
25 comprise a backing layer which is impermeable to the drug, a drug reservoir  
26 which can contain a permeation enhancer or permeation enhancer mixture  
27 in addition to the drug, a contact adhesive layer, and a rate controlling  
28 membrane positioned between the drug reservoir and contact adhesive.  
29 The layers are typically laminated or heat sealed together to produce a  
30 transdermal device.

1 It is known in the transdermal art to provide the drug reservoir with  
2 an initial amount of drug at a concentration at or above its saturation  
3 concentration in the reservoir in order to maintain a unit activity source of  
4 the drug so that the delivery of drug from the device will remain substantially  
5 constant over the intended delivery period. Subsaturated systems, such as  
6 disclosed in US Patent Nos. 4,379,454, 4,908,027, 5,004,610, and 5,344,656  
7 are also known in the art.

8 In addition to providing the drug in the drug reservoir, it is also known  
9 to preload the contact adhesive with an amount of the drug. For example,  
10 US Patent Nos. 4,201,211, 4,588,580, and 4,832,953 disclose transdermal  
11 drug delivery devices wherein the contact adhesive layer is prepared by  
12 solvent casting a mixture of the drug and adhesive. Typically, the preloaded  
13 amount corresponds to the amount necessary to provide an initial loading  
14 dose which creates a concentration gradient across skin and saturates the  
15 skin binding sites underlying the device with the drug to be delivered.  
16 Additionally, US Patent No. 4,832,953 discloses heating a laminate system  
17 comprising a dispersion of a liquid in a non-aqueous matrix in order to prevent  
18 formation of a crystalline hydrate.

19 In addition, Cleary "Transdermal Delivery Systems: A Medical  
20 Rationale", Topical Drug Bioavailability, Bioequivalence, and Penetration,  
21 Plenum Press 1993, pp 17 - 68, provides additional background information  
22 regarding commercially available transdermal drug delivery systems. A  
23 reasonably complete summary of the factors involved in percutaneous  
24 absorption of drugs may be found in Govil, "Transdermal Drug Delivery  
25 Devices", Drug Delivery Devices, Marcel Dekker, Inc. 1988, pp 385 - 419;  
26 Chien "Transdermal Systemic Drug Delivery Recent Development and Future  
27 Prospects", S.T.P. Pharma Sciences, Vol. 1, No. 1, pp 5 - 23, 1991; and  
28 Cleary "Transdermal Drug Delivery", Skin Permeation Fundamentals and  
29 Application, pp 207 - 237, 1993.

1       The transdermal route of parenteral delivery of drugs provides many  
2 advantages, and transdermal systems for delivering a wide variety of drugs or  
3 other beneficial agents have been described. Steroids including testosterone,  
4 for example, have been studied for their suitability for transdermal delivery  
5 and transdermal drug delivery systems for delivering testosterone are  
6 disclosed in the prior art. Current transdermal testosterone systems can be  
7 generally classified as either scrotal or non-scrotal systems. Each has its own  
8 advantages and disadvantages.

9       Scrotal systems such as described in US Patent Nos. 4,704,282,  
10 4,725,439, and 4,867,982, are more limited as to the available surface  
11 area for drug delivery while, on the other hand, they do not require the  
12 use of permeation enhancers. Non-scrotal systems such as described in  
13 US Patent Nos. 5,152,997 and 5,164,990, while not as limited in area of  
14 application, require the use of multiple permeation enhancers and are thus  
15 susceptible to the problems attendant therewith, particularly irritation. Irritation  
16 occurs as the skin reacts to topically applied substances, particularly those  
17 maintained under occlusion, by blistering or reddening accompanied by  
18 unpleasant burning, itching, and stinging sensations. It is desirable to keep  
19 the number of possibly irritating substances in a transdermal delivery device  
20 to a minimum.

21       More specifically, US Patent Nos. 4,704,282, 4,725,439, and  
22 4,867,982 disclose the transdermal administration of testosterone through  
23 intact scrotal skin. These patents teach that scrotal skin provides a five fold  
24 increase in permeability to testosterone over non-scrotal skin. Testosterone  
25 is provided in an ethylene vinyl acetate copolymer matrix and is delivered  
26 through scrotal skin without the use of permeation enhancers.

27       US Patent Nos. 5,152,997 and 5,164,990 disclose the transdermal  
28 administration of testosterone through areas of intact, non-scrotal skin. The  
29 5,164,990 patent requires an ethanol carrier and additionally includes a  
30 permeation enhancer or permeation enhancer mixture such as glycerol

1 monooleate and methyl laurate in order to deliver therapeutically effective  
2 amounts of testosterone through non-scrotal skin.

3         Additionally, US Patent No. 5,223,262 discloses a system for  
4 transdermally delivering a hydrophobic alkanol soluble active agent to the  
5 skin at a constant rate utilizing a lower alkanol penetration enhancer. The  
6 system comprises an overlying solvent reservoir containing a lower alkanol  
7 solvent and a drug reservoir containing an active agent in aqueous alkanol.  
8 The two reservoirs are separated by a one way membrane permeable to the  
9 alkanol solvent and substantially impermeable to the active agent and water.

10         WO 96/35427 discloses a transdermal therapeutic system for the  
11 delivery of testosterone which comprises an alcoholic carrier saturated with  
12 testosterone and is free of any permeation enhancers. The release rate of  
13 the active agent is regulated by the adhesive layer.

14         WO 97/10812 discloses methods for manufacturing transdermal drug  
15 delivery systems containing supersaturated drug reservoirs which obtain  
16 higher drug fluxes. The method involves heating the drug reservoir  
17 components to a predetermined temperature and subsequently cooling the  
18 drug reservoir components in order to provide a supersaturated reservoir  
19 such that it contains only a single phase of drug and reservoir material.

20         As noted above, it is often desirable to preload the adhesive with an  
21 amount of drug in excess of the saturation concentration and this has been  
22 done by premixing the drug into the adhesive. However, the process of  
23 premixing a drug into the adhesive layer, though enabling an amount of drug  
24 in excess of saturation to be initially added to the adhesive, presents  
25 considerable practical problems. The drug must be sent to the adhesive  
26 supplier to be mixed with the adhesive and subsequently sent back to the  
27 manufacturing site where the device is ultimately manufactured. This  
28 requires undesirable shipping, time, and perhaps most significantly, this

1 process requires particular facilities at the site of the adhesive supplier which  
2 conform with regulatory demands for the manufacture of drug delivery  
3 devices.

#### 4 5 DISCLOSURE OF THE INVENTION

6  
7 According to this invention, we have eliminated the need to premix  
8 the body contacting layer of a drug delivery device with the drug, while still  
9 producing an end product having suitable amounts of drug in excess of  
10 saturation in layers other than the drug reservoir, such as the contact  
11 adhesive of a transdermal drug delivery device.

12 Accordingly, one aspect of the invention is to provide an improved  
13 method of providing a drug delivery device with a loading dose.

14 Another aspect of the invention is to provide an improved process of  
15 manufacturing drug delivery devices whereby a desired amount of drug may  
16 be provided in the various layers of the drug delivery device and to devices  
17 made therefrom.

18 Another aspect of the invention is to eliminate the need to preload the  
19 contact adhesive of a transdermal drug delivery device with the drug in order  
20 to obtain an end product having an amount of drug in excess of saturation in  
21 the adhesive.

22 Another aspect of this invention is to provide an improved therapeutic  
23 transdermal system for the delivery of testosterone through intact, non-scrotal  
24 skin in order to achieve therapeutically effective blood levels of testosterone  
25 in a patient.

26 These and other objects and advantages of this invention will be  
27 readily apparent from the following description with reference to the  
28 accompanying figures.

## BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a cross-sectional view of one embodiment of the transdermal drug delivery system according to this invention.

FIG. 2(a) is a cross-sectional view of one embodiment of a transdermal drug delivery device prior to heat equilibration.

FIG. 2(b) is a cross-sectional view of one embodiment of a transdermal drug delivery device during heat equilibration.

FIG. 2(c) is a cross-sectional view of one embodiment of a transdermal drug delivery device after heat equilibration.

FIG. 3 depicts testosterone release rates from systems subjected to various heat equilibration procedures.

FIG. 4 depicts the effect of exposure time at 40° C on the initial fentanyl release rate from a transdermal device.

## DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term "drug" is to be construed in its broadest sense to mean any material which is intended to produce some biological, beneficial, therapeutic, or other intended effect, such as permeation enhancement, for example, on the organism to which it is applied.

As used herein, the term "excess of saturation" refers to a condition wherein drug exists in both a solid phase representing the excess and a dissolved phase which is at saturation in the carrier.

As used herein, the term "loading dose" refers to the amount of drug present in the adhesive layer or other body contacting layer other than the drug reservoir in excess of the saturation concentration.

As used herein, the term "rapidly cooling" refers to a cooling process which takes place over a period of time which is shorter than the period of time at which the device is maintained at an elevated temperature and



1 preferably to a time period over which there is no subsequent reequilibration  
2 of the drug containing layers.

3 As used herein, the term "substantial portion" refers to at least 60% of  
4 the administration period.

5 As used herein, the term "therapeutically effective" refers to the  
6 amount of drug or the rate of drug administration needed to effect the desired  
7 therapeutic result.

8 As used herein, the term "transdermal" refers to the use of skin,  
9 mucosa, and/or other body surfaces as a portal for the administration of drugs  
10 by topical application of the drug thereto.

11 According to this invention, it has been discovered that a  
12 predetermined amount of a drug can be introduced into layers of a drug  
13 delivery device which are initially free of drug in excess of saturation, and  
14 the amount thereof effectively controlled, by performing a heat equilibration  
15 process wherein the device is subjected to an elevated temperature for a  
16 predetermined period of time and thereafter rapidly cooled to ambient  
17 conditions. The process enables a greater amount of drug to migrate at a  
18 much quicker rate into the layers initially free of drug in excess of saturation,  
19 such as the rate control membrane and adhesive layers of a transdermal  
20 device, than is possible by simply allowing the device to equilibrate at room  
21 temperature. The process also allows the layers initially free of drug in  
22 excess of saturation to retain predetermined amounts of drug in excess of  
23 saturation, after rapidly cooling to ambient conditions. This process  
24 eliminates the need to mix the drug and body contacting layer such as the  
25 adhesive layer of a transdermal delivery device at a site other than the  
26 location of manufacture of the device in order to provide a desired loading  
27 dose in the body contacting layer.

28 The process of the invention may be practiced so as to provide a  
29 desired concentration of any drug in any of the particular layers of the final  
30 system by selecting an appropriate drug loading in excess of saturation in one

1 of the layers of the device, usually the drug reservoir, and selecting an  
2 appropriate time and temperature at which to conduct the heat equilibration  
3 process. The temperature selected for the equilibration process must be  
4 below that which causes degradation of the drug(s) or which causes other  
5 deleterious effects such as undesirable phase changes in the components of  
6 the device and is selected such that the drug remains at least at saturation in  
7 the layer at the elevated temperature. Temperatures useful in the present  
8 invention range from about 30° - 60° C, preferably 35° - 45° C. Once the  
9 temperature is selected, the time may be varied anywhere from about 8 hours  
10 to 3 weeks, depending upon the desired loading dose of drug to be delivered.  
11 A preferred range of times useful in the practice of the present invention is  
12 between about 1 to 10 days.

13 After the heating process, the devices are rapidly cooled to ambient  
14 conditions. The cooling step is performed such that drug is provided in  
15 excess of saturation in the desired layer(s) of the device. Preferably, the  
16 cooling process comprises subjecting the devices to a temperature below  
17 the elevated temperature for a period of time less than that at which the  
18 devices are subjected to the heating process. Preferred temperatures for  
19 the rapid cooling are at ambient conditions and preferred cooling times are  
20 from 6 hours to 5 days and most preferably from 6 to 36 hours.

21 This invention finds applicability with any type of drug delivery device  
22 which utilizes a loading dose of drug in one of its layers. For example, drug  
23 delivery systems such as those disclosed in US Patent Nos. 3,854,480 and  
24 3,938,515 may be used in the practice of this invention in order to provide the  
25 outer polymeric membrane with a loading dose of drug.

26 A preferred embodiment of this invention is directed to controlling the  
27 amount of drug migrating into the contact adhesive of a transdermal drug  
28 delivery device. By controlling the amount of drug which migrates from the  
29 drug reservoir into the contact adhesive, the initial loading dose of drug  
30 delivered can be effectively controlled in order to achieve a desired input of

1 drug to saturate skin binding sites without requiring the drug to be directly  
2 preloaded into the adhesive.

3 A particularly preferred embodiment is directed to transdermal drug.  
4 delivery devices for the administration of a drug at a substantially constant  
5 rate throughout an intended administration period wherein the drug reservoir  
6 contains drug at or in excess of saturation throughout the delivery period.  
7 According to this particularly preferred embodiment, the drug reservoir is  
8 initially provided with drug in excess of saturation and the adhesive and rate  
9 control membrane are initially drug-free. During heat equilibration the  
10 solubility of the drug in the reservoir and other layers increases from that at  
11 ambient conditions and the other layers will become saturated with the drug  
12 at this increased solubility level. After the heat equilibration process and  
13 cooling of the device to ambient conditions, the decrease in solubility of the  
14 other layers will cause precipitation of the drug in excess of saturation which  
15 will then remain in these other layers as a loading dose. The initial loading of  
16 drug in the reservoir is preferably selected so that the reservoir remains  
17 saturated with drug throughout the entire process.

18 Practice of this invention avoids the problems of preloading drug  
19 directly into the adhesive and provides an amount of drug in the adhesive  
20 greater than that possible from equilibration at normal conditions.  
21 Additionally, providing the drug reservoir and the contact adhesive each with  
22 drug at or in excess of saturation helps to prevent back flux of drug from the  
23 contact adhesive to the drug reservoir.

24 In accordance with the particularly preferred embodiment, the  
25 inventors have also discovered that testosterone may be effectively  
26 transdermally administered to hypogonadal males through non-scrotal skin  
27 with a lower incidence of skin irritation from a device of this invention  
28 comprising an amount of testosterone in excess of its saturation  
29 concentration in an ethanol carrier without additional permeation enhancers.  
30 Approximately 5-6 mg of testosterone may be transdermally delivered over

1 24 hours in order to achieve a mean serum testosterone concentration in  
2 hypogonadal males above the low end of the normal range for men (275-300  
3 ng/dL) and a mean maximum testosterone concentration at the mid-normal  
4 range of about 500-600 ng/dL. This is contrary to the teachings of US Patent  
5 Nos. 5,152,997 and 5,164,990 which suggest the need to provide  
6 testosterone at a condition below saturation together with permeation  
7 enhancers in addition to ethanol in order to achieve effective testosterone  
8 concentrations by transdermal administration through non-scrotal skin.  
9 Furthermore, the ethanol and testosterone are provided in a single reservoir,  
10 thus simplifying the manufacture of the device.

11 Referring now to Figure 1, a drug delivery device 10 comprising an  
12 aqueous gel reservoir 2 according to this invention is shown. Delivery device  
13 10 comprises a backing member 3 which serves as a protective cover for the  
14 device, imparts structural support, and substantially keeps components in  
15 device 10 from escaping the device. Device 10 also includes reservoir 2,  
16 which contains the drug with or without a permeation enhancer, and bears on  
17 its surface distant from backing member 3, a rate-controlling membrane 4 for  
18 controlling the release of drug and/or permeation enhancer from device 10.  
19 The outer edges of backing member 3 overlay the edges of reservoir 2 and  
20 are joined along the perimeter with the outer edges of the rate-controlling  
21 membrane 4 in a fluid-tight arrangement. This sealed reservoir may be  
22 effected by pressure, fusion, adhesion, an adhesive applied to the edges,  
23 or other methods known in the art. In this manner, reservoir 2 is contained  
24 wholly between backing member 3 and rate-controlling membrane 4. On the  
25 skin-proximal side of rate-controlling membrane 4 are an adhesive layer 5  
26 and a strippable liner 6 which would be removed prior to application of the  
27 device 10 to the skin.

1 According to the particularly preferred embodiment, the drug  
2 reservoir 2 is initially provided with a drug loading comprising an excess  
3 amount of drug beyond the saturation concentration of the drug in the  
4 reservoir such that, after heat equilibration according to this invention,  
5 the reservoir is maintained at a condition at or above saturation throughout  
6 a substantial portion of the predetermined drug administration period. This  
7 provides that the system will contain sufficient drug to provide the contact  
8 adhesive with the desired loading dose of drug during the heat equilibration  
9 and that the drug reservoir will contain sufficient drug in order to achieve the  
10 desired serum concentration levels for the intended period of administration.  
11 Additionally, maintaining the drug reservoir at or in excess of saturation  
12 provides for a substantially constant rate of administration.

13 To effect the heat equilibration process of this invention according to  
14 this particularly preferred embodiment, the drug delivery device with the drug  
15 reservoir comprising drug in excess of saturation is subjected to an elevated  
16 temperature for a predetermined period of time. Figure 2 (a) depicts drug  
17 delivery device 20 with excess drug 21 in the drug reservoir 22 as it is  
18 provided prior to heat equilibration. The device 20 also comprises backing 23,  
19 rate control membrane 24, contact adhesive 25, and release liner 26. Upon  
20 heating the device 20 to the predetermined temperature the solubility of the  
21 drug in all of the layers increases. Therefore, as long as the drug reservoir  
22 layer remains saturated with drug during the predetermined time period,  
23 drug migrates from the drug reservoir into the adjoining layers 24 and 25  
24 of the device at an accelerated rate due to the shift in equilibrium, as depicted  
25 in Figure 2(b). The shift in equilibrium also allows for a greater amount of  
26 drug to migrate into the adjoining layers, such as the contact adhesive 25,  
27 due to the increased solubility of the drug in the adhesive at the elevated  
28 temperature. After the predetermined time period, the device is removed from  
29 the elevated temperature and allowed to cool to ambient conditions. As the  
30 temperature decreases, the solubility of the drug in the adhesive also

1 decreases, leaving an amount of drug 21 in excess of saturation in the  
2 contact adhesive at ambient conditions, as depicted in Figure 2(c).

3 The amount of drug present in the therapeutic drug delivery device and  
4 required to achieve an effective therapeutic result depends on many factors,  
5 such as the minimum necessary dosage of the drug of the particular  
6 indication being treated; the solubility and permeability of the carrier and  
7 adhesive layer; and the period of time for which the device will be fixed to  
8 the skin. The minimum amount of drug is determined by the requirement  
9 that sufficient quantities of drug must be present in the device to maintain  
10 the desired rate of release over the given period of application. The  
11 maximum amount for safety purposes is determined by the requirement  
12 that the quantity of drug present does not produce toxic effects. Generally,  
13 the maximum concentration is determined by the amount of drug that can be  
14 received in the carrier without producing adverse histological effects such as  
15 irritation, an unacceptably high initial loading dose of drug into the body, or  
16 adverse effects on the characteristics of the delivery device such as the loss  
17 of tackiness, viscosity, or deterioration of other properties.

18 The initial loading of drug in the carrier will determine the useful life of  
19 the device, typically from 8 hours to seven days. The invention can be used  
20 for such time periods, however, certain preferred embodiments are  
21 particularly adapted for administration periods of up to about 24 hours. As  
22 discussed with respect to the particularly preferred embodiment, the drug is  
23 initially present in the carrier at a concentration at or in excess of saturation.  
24 The drug may, however, be present at a level below saturation during use  
25 without departing from this invention as long as the drug is continuously  
26 administered to the skin or mucosal site in an amount and for a period of  
27 time sufficient to provide the desired therapeutic rate.

28 The backing may be a breathable or occlusive material including, but  
29 not limited to, polyethylene, polyurethane, polyester or ethylene vinyl acetate  
30 films. A polyethylene terephthalate-ethylene vinyl acetate backing is

1 preferred. If an ethylene vinyl acetate is employed as the backing, preferably,  
2 it has a vinyl acetate content of 33% or 40%.

3 The rate-controlling membrane may be fabricated from permeable,  
4 semipermeable or microporous materials which are known in the art to control  
5 the rate of agents into and out of delivery devices and having a permeability  
6 to the permeation enhancer lower than that of drug reservoir 12. Suitable  
7 materials include, but are not limited to, polyethylene, polypropylene, polyvinyl  
8 acetate, ethylene n-butyl acetate and ethylene vinyl acetate copolymers. The  
9 rate control membrane may also include an amount of mineral oil or other  
10 diffusive medium as disclosed in US Patent No. 3,797,494.

11 The reservoir formulation may be aqueous or non-aqueous based.  
12 Aqueous formulations typically comprise water or water/ethanol and about  
13 1-5 wt% of a gelling agent, an example being a hydrophilic polymer such as  
14 hydroxyethylcellulose or hydroxypropylcellulose. Typical non-aqueous gels  
15 are comprised of silicone fluid or mineral oil. Mineral oil-based gels also  
16 typically contain 1-2 wt% of a gelling agent such as colloidal silicon dioxide.  
17 The suitability of a particular gel depends upon the compatibility of its  
18 constituents with the drug and the permeation-enhancing mixture, if used,  
19 in addition to any other components in the formulation.

20 When using a non-aqueous based formulation, the reservoir matrix is  
21 preferably composed of a hydrophobic polymer. Suitable polymeric matrices  
22 are well known in the transdermal drug delivery art, and examples are listed  
23 in the above-named patents. A typical laminated system would consist  
24 essentially of a polymeric membrane and/or matrix such as ethylene vinyl  
25 acetate (EVA) copolymers, such as those described in US Pat. No.  
26 4,144,317, preferably having a vinyl acetate (VA) content in the range of  
27 from about 9% up to about 60% and more preferably about 9% to 40% VA.  
28 Polyisobutylene/oil polymers containing from 4-25% high molecular weight  
29 polyisobutylene and 20-81% low molecular weight polyisobutylene with the

1 balance being an oil such as mineral oil or polybutene may also be used as  
2 the matrix material.

3 Suitable adhesives are well known in the art and include, but are not  
4 limited to, silicone and/or acrylate polymers including mixtures and graft  
5 copolymers thereof, polyisobutylene (PIB) adhesives comprising mixtures of  
6 low and high molecular weight PIB's and an optional amount of mineral oil or  
7 polybutene, such as those described in US Patent No. 5,508,038, styrene-  
8 butadiene copolymers, and styrene-isoprene copolymers with tackifier(s).

9 Although any drug which is suitable for transdermal administration can  
10 be delivered according to this invention, certain drugs are particularly suited  
11 for administration from devices according to this invention. Testosterone and  
12 its esters constitute a preferred drug for delivery according to this invention,  
13 particularly for use in the treatment of hypogonadic males. Other preferred  
14 drugs include hormones, particularly steroids, estrogens such as estradiol  
15 and its esters, anabolic agents such as nandrolone and its esters,  
16 progestogens such as progesterone and its esters, corticosteroids, and  
17 narcotic agents.

18 The surface area of the device of this invention can vary from about  
19 5 cm<sup>2</sup> to about 75 cm<sup>2</sup>. A typical device, however, will have a surface area  
20 within the range of about 20-60 cm<sup>2</sup>. A typical transdermal device according  
21 to this invention is fabricated as an approximately 60 cm<sup>2</sup> generally elliptical  
22 or rectangular patch with rounded corners.

23 The drug delivery devices of this invention may also contain other  
24 permeation enhancers, stabilizers, dyes, diluents, pigments, carriers, inert  
25 fillers, antioxidants, excipients, gelling agents, anti-irritants, vasoconstrictors,  
26 as are known to the art.

27 The devices of this invention can be designed to effectively deliver  
28 drug for an extended period of time from several hours up to seven days or  
29 longer. Seven days is generally the maximum time limit for application of a  
30 single device because the adverse effect of occlusion of a skin site increases



1 with time and a normal cycle of sloughing and replacement of the skin cells  
2 occurs in about seven days.

3 According to the particularly preferred embodiment for the transdermal  
4 administration of testosterone, the drug reservoir comprises 20 - 30 wt%  
5 testosterone, 68 - 80 wt% ethanol, and 1 - 2 wt% of a gelling agent such as  
6 hydroxypropyl cellulose, the rate control membrane comprises an ethylene  
7 vinyl acetate copolymer having a vinyl acetate content of 5 - 30 wt%,  
8 preferably 9 - 18%, and the adhesive comprises a polyisobutylene mixture  
9 comprising high molecular weight PIB/low molecular weight PIB/mineral oil in  
10 a ratio of .75-1.25/1-1.5/1.5-2.5, most preferably 1/1.25/2.

11 The aforementioned patents describe a wide variety of materials which  
12 can be used for fabricating the various layers and components of the drug  
13 delivery devices according to this invention. This invention, therefore,  
14 contemplates the use of materials other than those specifically disclosed  
15 herein, including those which may hereafter become known to the art and to  
16 be capable of performing the necessary functions.

17 The following examples are offered to illustrate the practice of the  
18 present invention and are not intended to limit the invention in any manner.

19

## 20 EXAMPLE 1

21

22 Transdermal delivery systems for the administration of testosterone  
23 through non-scrotal skin were made as follows. A reservoir gel comprising  
24 26 wt.% testosterone, 1-2 wt.% hydroxypropyl cellulose, and the remainder  
25 95% ethanol was prepared by mixing testosterone, 95% ethanol and  
26 adding hydroxypropyl cellulose with mixing. The gel loading was 21 mg  
27 testosterone / cm<sup>2</sup>. *cellulose ethanol*

28 A contact adhesive composition was made by mixing polyisobutylene  
29 (MW 1200000), polyisobutylene (MW 35000) and light mineral oil in a weight  
30 ratio of 1:1.25:2. A 50 micron thick layer of the contact adhesive was cast

*pressure  
sensitive  
adhesive*

1 onto a 75 micron thick film of siliconized polyethylene terephthalate release  
2 liner. The contact adhesive side of the resulting two layer subassembly was  
3 laminated to a 50 micron thick film of ethylene vinyl acetate (EVA) copolymer  
4 (9% vinyl acetate). The gelled testosterone-ethanol mixture was placed on  
5 the EVA membrane. A backing member comprised of aluminized  
6 polyethylene terephthalate with an EVA heat sealable coating was laid over  
7 the gels and heat-sealed to the EVA copolymer using a rotary heat seal  
8 machine. Finished systems were punched from laminate using a circular  
9 punch and placed in sealed pouches to prevent loss of volatile components.

10 Systems were then subjected to 35° C, 40° C, or 50° C for a seven day  
11 period and release rates were tested at room temperature and compared with  
12 systems kept at room temperature for 1 month in order to observe the effect  
13 of temperature on the loading dose.

14 The release liner of the laminate was removed and the system was  
15 then mounted on a Teflon® rod. A known volume of receptor solution  
16 (0.10% phenol/H<sub>2</sub>O) was then placed in a test tube and was equilibrated  
17 at 35°C. The Teflon rod with the attached system was then placed in a water  
18 bath at 35°C. Mixing was accomplished by attachment to a motor which  
19 caused constant vertical mixing.

20 At given time intervals, the entire receptor solution was removed from  
21 the test tubes and replaced with an equal volume of fresh receptor solutions  
22 previously equilibrated at 35°C. The receptor solutions were stored in capped  
23 vials at 4°C until assayed for testosterone content by HPLC. From the drug  
24 concentration and the volume of the receptor solutions, the area of  
25 permeation and the time interval, the flux of the drug was calculated as  
26 follows: (drug concentration X volume of receptor)/(area x time) = flux  
27 ( $\mu\text{g}/\text{cm}^2 \cdot \text{hr}$ ).

Figure 3 shows the effect of heat equilibration on the testosterone release rate. From the results depicted in Figure 3, it is seen that temperature demonstrated the most significant effect on testosterone release rate during the 0-2 hour initial delivery period, which corresponds to the delivery of the loading dose. The loading dose for this system corresponds approximately to the cumulative release of testosterone during the 0-2 hour period. The effect of heat equilibration on the loading dose, as measured by the cumulative release of testosterone during the 0-2 hour period, is shown in Table 1. As seen in Table 1, the loading dose increased with the temperature of the heat equilibration process.

TABLE 1

Effect of Heat Equilibration  
On Loading Dose of Testosterone

Group	0-2 Hour Cumulative Release ( $\mu\text{g}/\text{cm}^2$ )
I	6.7
II	26.0
III	28.2
IV	46.8

Group I was stored at room temperature for 1 month.

Group II was placed in oven at 35° C for 7 days.

Group III was placed in oven at 40° C for 7 days.

Group IV was placed in oven at 50° C for 7 days.

#### EXAMPLE 2

Transdermal therapeutic systems comprising an aqueous ethanolic gel were prepared according to the following procedure. Fentanyl base was added to 95% ethanol and stirred to dissolve the drug. Purified water was then added to generate a mixture containing 14.7 mg/g of fentanyl in a 30% ethanol-water solvent. 2% of hydroxyethyl cellulose gelling agent was added slowly to the solution with stirring and mixed until a smooth gel was obtained (approximately 1 hour). A 0.05 mm thick contact adhesive layer was formed on a fluorocarbon-diacrylate treated polyester film which comprised the

1 release liner for the system by solution casting an amine resistant silicone  
2 medical adhesive onto the polyester film from a solution in  
3 trichlorotrifluorethane. A 0.05 mm thick rate controlling membrane comprised  
4 of EVA (9% VA) was pressure laminated to the exposed adhesive. A backing  
5 member comprised of a multilaminate of polyethylene, aluminum, polyester,  
6 and EVA was also provided and the aqueous gel pouched between the  
7 backing member and the release liner/adhesive/rate controlling membrane  
8 on a rotary heat-seal machine at a gel loading of 15 mg/cm<sup>2</sup>. Sealed pouches  
9 in sizes of 10 cm<sup>2</sup> were die cut and immediately pouched to avoid loss of  
10 ethanol.

11 The effect of heat equilibration on 10 cm<sup>2</sup> systems prepared according  
12 to the above procedure was tested. Systems were subjected to various  
13 temperature/time regimens and thereafter kept at 25° C. The cumulative  
14 release of fentanyl during the initial 0-2 hour period was measured using the  
15 procedure set forth in Example 1 to test release rates. The release rates  
16 were measured after storage at 25° C for two months. The results are shown  
17 in Table 2.

TABLE 2

Effect of Heat Equilibration on Fentanyl Loading Dose

Group	0-2 hr release (µg/hr)
I	208.9
II	246.3
III	404.2
IV	445.1

20 Group I was placed in oven at 30° C for 7 days before storage at 25° C.  
21 Group II was placed in oven at 40° C for 3 days before storage at 25° C.  
22 Group III was placed in oven at 51° C for 1 day before storage at 25° C.  
23 Group IV was placed in oven at 60° C for 1 day before storage at 25° C.  
24

Table 2 shows that the cumulative release of drug during the initial 0-2 hour period of administration increases as the temperature of the heat equilibration process increases. This initial 0-2 hour delivery period corresponds approximately to the delivery of the loading dose. After 2 months storage at room temperature, no detectable movement of fentanyl back into the drug reservoir from the adhesive was observed. It is seen from Table 2 that the release of fentanyl during the 0-2 hour period (loading dose) increases with temperature of heat equilibration.

### Example 3

The effect of exposure time at an elevated temperature heat equilibration process was investigated. Systems prepared according to Example 2 were kept at 40° C and release rates were taken at 0, 3, 7, and 14 day intervals. Figure 4 shows the effect of storage at 40 ° C on the initial release of fentanyl during the 0-2 hour period (loading dose) after delivery is initiated. As seen in Figure 4, the loading dose increased with time of exposure.

### Example 4

10 cm<sup>2</sup> systems were prepared according to Example 2. Some of these systems were subjected to 40° C for four days, while the remaining systems were kept at room temperature. *In vitro* release profiles using the procedure set forth in Example 1 were determined for each set of systems. The average loading dose for these systems, measured by the 0-2 hour cumulative release, was determined to be 199.00 µg/hr for the room temperature systems and 282.25 µg/hr for the systems kept at 40° C for four days. An amount of solid drug was observed in the drug reservoir gel of each set of systems before performing the release rate tests, indicating that the

1 drug reservoir comprised an amount of drug in excess of saturation. Solid  
2 drug was observed in the drug reservoir gel of the heat equilibrated systems  
3 as they were removed from the oven.

4 Although the above examples have described the process as being  
5 performed on pouched systems it is also possible to perform this process  
6 prior to either system punching or pouching in those cases where there are  
7 no concerns about loss of volatile components.

8 The invention has been described in detail with particular reference to  
9 certain preferred embodiments thereof, but it will be understood that  
10 variations and modifications can be affected within the scope and spirit of the  
11 invention.

**CLAIMS**

What is claimed is:

1. An improved method for manufacturing a drug delivery device having more than one layer containing a concentration of drug in excess of saturation which method comprises:

forming a device comprising at least one layer initially containing drug in excess of saturation and at least one other layer initially free of drug in excess of saturation;

subjecting the device to an elevated temperature for a predetermined period of time sufficient to cause a predetermined amount of a drug to migrate from said layer initially containing drug in excess of saturation into the other layers of the device that are initially free of drug in excess of saturation; and rapidly cooling the device to ambient conditions.

2. The method of claim 1 further comprising selecting a drug loading of the drug in the layer initially containing drug in excess of saturation in an amount sufficient to provide at least one of the other layers that are initially free of drug in excess of saturation with an amount of drug in excess of saturation after the rapid cooling step.

3. The method of claim 2 wherein the drug loading is selected such that the layer initially containing drug in excess of saturation comprises drug in excess of saturation after the rapid cooling step.

4. An improved method for manufacturing transdermal drug delivery devices comprising:

(a) forming a drug reservoir on a backing layer, the drug reservoir comprising a drug loading comprising drug in excess of saturation;

(b) forming a contact adhesive layer on a release liner, said contact adhesive being free of drug in excess of saturation;

(c) placing the drug reservoir in drug transferring relation to said adhesive layer to form the device;

1           (d)     subjecting the device to an elevated temperature for a  
2     predetermined period of time in order to cause enhanced migration of the  
3     drug from the drug reservoir into the contact adhesive; and

4           (e)     rapidly cooling the device to ambient conditions.

5           5.     A method according to claim 4 further comprising selecting the  
6     drug loading in order to provide the adhesive with an amount of drug in  
7     excess of saturation after the rapid cooling step.

8           6.     A method according to claim 5 further comprising selecting the  
9     drug loading in order to provide the drug reservoir with an amount of drug in  
10    excess of saturation after the rapid cooling step.

11          7.     A method according to claim 4 further comprising selecting the  
12    temperature and time in order to provide that the adhesive comprises an  
13    amount of drug in excess of saturation after the rapid cooling step.

14          8.     A method according to claim 7 wherein the temperature  
15    selected is between 30 and 60 °C and the time selected is between 12 hours  
16    and 20 days.

17          9.     A method according to claim 8 wherein the temperature  
18    selected is between 35 and 45 °C and the time selected is between  
19    1 - 10 days.

20          10.    A method according to claim 4 wherein a rate control membrane  
21    is provided in between the contact adhesive and the drug reservoir.

22          11.    A method according to claim 4 wherein the drug reservoir  
23    comprises ethanol.

24          12.    A method according to claim 4 wherein the contact adhesive  
25    comprises polyisobutylene and mineral oil.

26          13.    A method according to claim 4 wherein the contact adhesive  
27    comprises an acrylate adhesive.

28          14.    A method according to claim 10 wherein the rate control  
29    membrane comprises an ethylene vinyl acetate copolymer having a vinyl  
30    acetate content of 6-60%.



1           15.    A device for the transdermal administration of testosterone  
2    through intact, non-scrotal skin comprising:

3           a)     a backing layer;

4           b)     a drug reservoir comprising testosterone dispersed within a  
5    carrier in an amount in excess of the saturation concentration of testosterone  
6    in the carrier ;

7           c)     means for maintaining the device in testosterone - transmitting  
8    relation with intact, non-scrotal skin,

9           wherein testosterone is administered through the skin at a substantially  
10   constant rate throughout a substantial portion of the administration period.

11          16.    A device according to claim 15 wherein the means for  
12   maintaining the device in testosterone - transmitting relation with intact, non-  
13   scrotal skin comprises a contact adhesive.

14          17.    A device according to claim 16 wherein said excess is sufficient  
15   to maintain testosterone at a level at or in excess of saturation in the drug  
16   reservoir and in the contact adhesive throughout a substantial portion of the  
17   administration period.

18          18.    A device according to claim 15 further comprising a rate control  
19   membrane on the skin proximal side of the drug reservoir.

20          19.    A device according to claim 15 wherein the carrier comprises an  
21   aqueous gel.

22          20.    A device according to claim 19 wherein the carrier comprises  
23   ethanol.

24          21.    A device according to claim 18 wherein the rate control  
25   membrane comprises an ethylene vinyl acetate copolymer having a vinyl  
26   acetate content of 5-30%.

27          22.    A device according to claim 21 wherein the vinyl acetate content  
28   is 9-18%.

1           23.    A device according to claim 16 wherein the adhesive comprises  
2   a blend of low molecular weight polyisobutylene and high molecular weight  
3   polyisobutylene.

4           24.    A device according to claim 23 wherein the ratio of low  
5   molecular weight polyisobutylene to high molecular weight polyisobutylene is  
6   1.25:1.

7           25.    A device for the transdermal administration of testosterone  
8   through intact, non-scrotal skin comprising:

9           a)    a backing layer;

10          b)    a drug reservoir containing testosterone at or in excess of  
11   saturation comprising:

12                  i) 20 - 30 wt% testosterone;

13                  ii) 68 - 80 wt% of a lower alcohol carrier; and

14                  iii) 1 - 2 wt% of a gelling agent,

15          c)    a rate control membrane on the skin-proximal side of the  
16   reservoir,

17          d)    means for maintaining the device in testosterone - transmitting  
18   relation with intact, non-scrotal skin,

19                  wherein testosterone is administered through the skin at a substantially  
20   constant rate throughout a substantial portion of the administration period.

1/3




FIG. 1




FIG. 2A




FIG. 2B




FIG. 2C

2/3





FIG. 3

3/3

**FIG. 4**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup>:</b> <b>A61K 31/565, A61L 15/44</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 98/00118</b> <b>(43) International Publication Date:</b> 8 January 1998 (08.01.98)
<b>(21) International Application Number:</b> PCT/US97/12545 <b>(22) International Filing Date:</b> 3 July 1997 (03.07.97)  <b>(30) Priority Data:</b> 60/012,124                      3 July 1996 (03.07.96)                      US  <b>(71) Applicant:</b> ALZA CORPORATION [US/US]; 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).  <b>(72) Inventors:</b> ENSCORE, David, J.; 2 Red Oak Drive, Sudbury, MA 01776 (US). CAMPBELL, Patricia, S.; 1410 Middlefield Road, Los Altos, CA 94301 (US). NEDBERGE, Diane, E.; 473 Arboleda Drive, Los Altos, CA 94024-4111 (US). FRAME, Richard, D.; 5043 Cape May Avenue, San Diego, CA 92017 (US).  <b>(74) Agents:</b> RAFA, Michael, J. et al.; Alza Corporation, 950 Page Mill Road, P.O. Box 10950, Palo Alto, CA 94303-0802 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>  <b>(88) Date of publication of the international search report:</b> 5 March 1998 (05.03.98)
<b>(54) Title:</b> DRUG DELIVERY DEVICES AND PROCESS OF MANUFACTURE		
<b>(57) Abstract</b>		
<p>An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/12545

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/565 A61L15/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No
X	EP 0 304 227 A (ALZA CORP) 22 February 1989 see page 5 - page 6; example 1 see claim 1 ---	1-9
X	PATENT ABSTRACTS OF JAPAN vol. 012, no. 333 (C-526), 8 September 1988 & JP 63 093714 A (SEKISUI CHEM CO LTD), 25 April 1988, see abstract	1
X	& DATABASE WPI Section Ch, Week 8822 Derwent Publications Ltd., London, GB; Class A96, AN 88-152039 & JP 63 093 714 (SEKISUI CHEM CO LTD) see abstract --- -/--	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex

## Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 January 1998

Date of mailing of the international search report

30/01/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/12545

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
P,X	WO 97 20550 A (ALZA CORP) 12 June 1997 see claims ---	1-7
P,X	WO 97 10812 A (CYGNUS THERAPEUTIC SYSTEMS) 27 March 1997 see claim 13 see page 25; example 3 see page 5, line 1 - line 22 see page 11, line 25 - page 13, line 7 ---	1,3-7
A	WO 92 07590 A (ALZA CORP) 14 May 1992 see page 10, line 28 - line 32 see page 14, line 25 - line 34 ---	1
X	WO 92 20377 A (ALZA CORP) 26 November 1992 see page 9, line 20 - line 29 see page 17 - page 18; example 1 see page 8, line 11 - line 24 see figure 3 ---	15-20
X	WO 95 09006 A (ALZA CORP ; TASKOVICH LINA TORMEN (US); YUM SU IL (US); LEE EUN SOO) 6 April 1995 see page 13, line 14 - line 20 see page 25 - page 26; example 4 ---	15-17
X	WO 94 06383 A (UNIV RUTGERS) 31 March 1994 see page 52 - page 54; example 8 ---	15-17
E	WO 97 24148 A (CYGNUS THERAPEUTIC SYSTEMS) 10 July 1997 see page 6, line 20 - line 23 see page 20 - page 26 ---	15-18
A	US 4 863 970 A (PATEL DINESH C ET AL) 5 September 1989 see column 12 - column 13; example IV ---	15
P,A	WO 96 35427 A (HEXAL AG ; FISCHER WILFRIED (DE); BRACHER DANIEL (DE)) 14 November 1996 see page 8 - page 9; example 1 ---	25
A	WO 96 19205 A (THERATECH INC) 27 June 1996 see page 11 - page 12; example 3 -----	15-25

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 97/12545

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0304227 A	22-02-89	US 4832953 A	23-05-89
		AU 600634 B	16-08-90
		AU 2060788 A	16-02-89
		CA 1331340 A	09-08-94
		DE 3878781 A	08-04-93
		DK 453488 A	14-02-89
		ES 2042754 T	16-12-93
		IE 61680 B	16-11-94
		JP 1066113 A	13-03-89
		JP 2610314 B	14-05-97
		PT 88269 B	31-01-96
WO 9720550 A	12-06-97	AU 1120097 A	27-06-97
WO 9710812 A	27-03-97	AU 6968296 A	09-04-97
WO 9207590 A	14-05-92	AU 657502 B	16-03-95
		AU 8956291 A	26-05-92
		CA 2091883 A	30-04-92
		EP 0555360 A	18-08-93
		JP 6502419 T	17-03-94
		NZ 240358 A	27-09-94
		US 5512292 A	30-04-96
		US 5376377 A	27-12-94
WO 9220377 A	26-11-92	AU 2010392 A	30-12-92
		MX 9202350 A	01-11-92
		US 5641504 A	24-06-97
WO 9509006 A	06-04-95	AU 679793 B	10-07-97
		AU 7924994 A	18-04-95
		AU 679794 B	10-07-97
		AU 7964794 A	18-04-95
		CA 2165802 A	06-04-95
		CA 2167526 A	06-04-95
		EP 0721348 A	17-07-96
		EP 0721349 A	17-07-96
		JP 9505278 T	27-05-97
		JP 9505279 T	27-05-97
		NZ 274711 A	26-11-96

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/12545

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9509006 A		NZ 275615 A	26-11-96
		WO 9509007 A	06-04-95
		US 5686097 A	11-11-97
WO 9406383 A	31-03-94	AU 4923493 A	12-04-94
		CN 1092287 A	21-09-94
		EP 0616514 A	28-09-94
WO 9724148 A	10-07-97	AU 1429697 A	28-07-97
US 4863970 A	05-09-89	DE 3779999 A	30-07-92
		EP 0267617 A	18-05-88
		ES 2042527 T	16-12-93
		JP 2660839 B	08-10-97
		JP 63211241 A	02-09-88
		KR 9601373 B	27-01-96
WO 9635427 A	14-11-96	DE 19517145 C	28-11-96
		AU 5805096 A	29-11-96
		NO 975140 A	10-11-97
WO 9619205 A	27-06-96	AU 4523396 A	10-07-96
		CA 2208132 A	27-06-96
		EP 0799029 A	08-10-97
		US 5662925 A	02-09-97
		ZA 9510786 A	20-06-96